An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma
Public ClinicalTrials.gov record NCT02726581. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and effectiveness of several combination therapies for Multiple Myeloma. Upon entry into the study, patients will be randomized (assigned by chance) to receive either: Group 1: nivolumab, pomalidomide and dexamethasone OR Group 2: pomalidomide and dexamethasone OR Group 3: nivolumab, elotuzumab, pomalidomide and dexamethasone. Enrollment is closed for all groups.
Study identification
- NCT ID
- NCT02726581
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 170 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Biological
- Elotuzumab Biological
- Pomalidomide Drug
- Dexamethasone Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2016
- Primary completion
- Mar 8, 2022
- Completion
- Mar 8, 2022
- Last update posted
- Mar 26, 2023
2016 – 2022
United States locations
- U.S. sites
- 72
- U.S. states
- 29
- U.S. cities
- 68
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0020 | Birmingham | Alabama | 35294-3300 | — |
| Local Institution - 0160 | Mobile | Alabama | 36608 | — |
| Local Institution - 0163 | Fayetteville | Arkansas | 72703 | — |
| Local Institution - 0118 | Bakersfield | California | 93309 | — |
| Local Institution - 0093 | Corona | California | 92879 | — |
| Local Institution - 0016 | Fountain Valley | California | 92708 | — |
| Local Institution - 0164 | La Jolla | California | 92037 | — |
| UC San Diego Moores Cancer Ctr | La Jolla | California | 92093-0698 | — |
| Local Institution - 0138 | Los Angeles | California | 90017 | — |
| Local Institution - 0155 | Los Angeles | California | 90095 | — |
| Local Institution - 0117 | Redondo Beach | California | 90277 | — |
| Local Institution - 0092 | Riverside | California | 92501 | — |
| Coastal Integrative Cancer Care | San Luis Obispo | California | 93401 | — |
| Local Institution - 0113 | Santa Maria | California | 93454 | — |
| Colorado Blood Cancer Institute | Denver | Colorado | 80218 | — |
| Poudre Valley Health Care | Fort Collins | Colorado | 80528 | — |
| Local Institution - 0116 | Grand Junction | Colorado | 81501 | — |
| Yale University School Of Medicine | New Haven | Connecticut | 06520 | — |
| Local Institution - 0147 | Washington D.C. | District of Columbia | 20007 | — |
| Local Institution - 0011 | Boynton Beach | Florida | 33426 | — |
| Florida Cancer Specialists S. | Fort Myers | Florida | 33916 | — |
| Local Institution - 0114 | Hollywood | Florida | 33021 | — |
| Cancer Specialists of North FL | Jacksonville | Florida | 32256 | — |
| Local Institution - 0082 | Pensacola | Florida | 32504 | — |
| Local Institution - 0126 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0130 | Tallahassee | Florida | 32308 | — |
| Local Institution - 0125 | West Palm Beach | Florida | 33401 | — |
| Local Institution - 0119 | Athens | Georgia | 30607 | — |
| Local Institution - 0009 | Atlanta | Georgia | 30318 | — |
| Local Institution - 0024 | Atlanta | Georgia | 30322 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Local Institution - 0035 | Chicago | Illinois | 60612 | — |
| Local Institution - 0111 | Fort Wayne | Indiana | 46845 | — |
| Indiana University Cancer Ctr | Indianapolis | Indiana | 46202 | — |
| Local Institution - 0018 | Bethesda | Maryland | 20817 | — |
| Local Institution - 0006 | Baltimore | Massachusetts | 21229 | — |
| Local Institution - 0123 | Worcester | Massachusetts | 01655 | — |
| Local Institution - 0150 | Ypsilanti | Michigan | 48197 | — |
| Local Institution - 0137 | Hattiesburg | Mississippi | 39401 | — |
| St. Louis Cancer Care, Llp | Bridgeton | Missouri | 63044 | — |
| Local Institution - 0128 | Kansas City | Missouri | 64132 | — |
| Local Institution - 0049 | Springfield | Missouri | 65806 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Local Institution - 0079 | Lincoln | Nebraska | 68510 | — |
| Local Institution - 0076 | Flemington | New Jersey | 08822 | — |
| Local Institution - 0002 | Hackensack | New Jersey | 07601 | — |
| Local Institution - 0095 | New Brunswick | New Jersey | 08903 | — |
| Local Institution - 0142 | Paramus | New Jersey | 07652 | — |
| Local Institution - 0010 | Buffalo | New York | 14263 | — |
| Broome Oncology LLC | Johnson City | New York | 13790 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Local Institution - 0017 | New York | New York | 10065 | — |
| Local Institution - 0001 | Durham | North Carolina | 27710 | — |
| Local Institution - 0096 | Winston-Salem | North Carolina | 27157 | — |
| Local Institution - 0012 | Columbus | Ohio | 43219 | — |
| University Of Oklahoma | Oklahoma City | Oklahoma | 73104 | — |
| Local Institution - 0145 | Portland | Oregon | 97213 | — |
| Local Institution - 0136 | Lancaster | Pennsylvania | 17604 | — |
| Local Institution - 0021 | Philadelphia | Pennsylvania | 19104 | — |
| Local Institution - 0036 | Sayre | Pennsylvania | 18840 | — |
| Local Institution - 0152 | Greenville | South Carolina | 29605 | — |
| Local Institution - 0069 | Germantown | Tennessee | 38138 | — |
| Tennessee Oncology, PLLC - SCRI - PPDS | Nashville | Tennessee | 37203 | — |
| Baylor Research Institute | Dallas | Texas | 75246 | — |
| Local Institution - 0044 | Houston | Texas | 77090 | — |
| Local Institution - 0037 | San Antonio | Texas | 78229 | — |
| Local Institution - 0046 | Temple | Texas | 76508-0001 | — |
| Local Institution - 0022 | Ogden | Utah | 84403 | — |
| Local Institution - 0153 | Salt Lake City | Utah | 84106 | — |
| Emily Couric Clinical Cancer Center | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Local Institution - 0144 | Seattle | Washington | 98108 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02726581, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 26, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02726581 live on ClinicalTrials.gov.